Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Oncopeptides AB ( (SE:ONCO) ) just unveiled an update.
Oncopeptides AB announced it will host a Capital Markets Update on November 13, 2025, to provide insights into its strategic direction and expanding role in the treatment of multiple myeloma. The event will feature presentations from international experts and company leaders, offering clinical, scientific, and market perspectives, which may influence the company’s market positioning and investment appeal.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a pharmaceutical company focused on developing therapies for the treatment of multiple myeloma, a type of blood cancer. The company is known for its innovative approach in the oncology sector, particularly with its proprietary PDC platform, which is aimed at addressing unmet medical needs in the treatment landscape.
Average Trading Volume: 5,241,021
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.33B
See more insights into ONCO stock on TipRanks’ Stock Analysis page.